Leslie Hammersmith Young Survival Coalition Champaign-Urbana
Thursday morning session: Clinical Connections from Bench to Bedside, Beckman Institute, 3:00 PM--3:30 PM
Abstract: Medical research empowers us to fight cancer, and advocacy empowers us to ensure that it addresses the needs of people affected by cancer. Advocacy helps us get through our cancer experiences, stand up for all people affected by cancer and gain a feeling of control over our own healthcare. Young Survival Coalition has staked out a powerful role as the voice for young women affected by breast cancer. Our Champaign-Urbana affiliate supports young women in Central Illinois through their breast cancer diagnosis and treatment, and we actively work to become educated cancer research advocates so that we can help all young women and end cancer for all people. We work to raise awareness and make improvements on issues of unique importance to young women. Survivors have been instrumental in shaping cancer research studies by helping to define which questions researchers need to address in order to improve the standard of care and quality of life issues most important to us. Educated advocates provide a necessary perspective, making sure researchers think about how their work helps us. This talk discusses the connections between cancer survivorship, cancer research and accelerating our progress towards ending cancer.
Speaker bio: Leslie Hammersmith is the eLearning Analyst in the Office of the Chief Information Officer at the University of Illinois Urbana-Champaign. She has over 14 years of experience in higher education and faculty development in educational technologies. Leslie is trained in Cancer Research Advocacy and is a Patient Advocate with Carle Cancer Center, where she reviews cancer research protocols. In 2009 Leslie was one of the founders of the Champaign-Urbana Affiliate of Young Survival Coalition, the premier global organization dedicated to the critical issues unique to young women who are diagnosed with breast cancer. Under her leadership, YSC C-U has grown to a recognized community organization to support young women facing breast cancer in Central Illinois. Leslie has participated in programs from Reasearch Advocacy Network and AACR Scientist Survivor Program, and continues to pursue professional development in advocacy.
I'm very excited to announce our next speaker, Leslie Hammersmith from the Young Survival Coalition of Champaign-Urbana.
Leslie is the e-learning analyst at the Office of the Chief Information Officer at the University of Illinois.
She has over 14 years of experience in higher education and faculty development in educational technologies.
Leslie is trained in cancer research advocacy and is a patient advocate with Carle Cancer Center, where she reviews cancer research protocols.
In 2009, Leslie was one of the founders of the Champaign-Urbana Affiliate of Young Survival Coalition,
the premier global organization dedicated to the critical issues unique to young women who are diagnosed with breast cancer.
Under her leadership, YSCU has grown to a recognized community organization to support young women facing breast cancer in central Illinois.
Leslie has participated in programs from Research Advocacy Network and AACR's Scientist Survivor Program
and continues to pursue professional development and advocacy. So let's welcome Leslie.
Thank you. Thank you very much for having me come here and coming in the late afternoon to listen and to my friends who are here.
I really appreciate that. So I'm loosely affiliated, well not loosely, but very closely affiliated with the University of Illinois
as an employee and with the Young Survival Coalition as one of our affiliate leadership members.
Let's see if I can make this work. Okay. So there's my disclaimer.
And I'm surprised that not more of you guys had this at the beginning of your PowerPoints,
because this is something I learned from going to ASCO and AACR and those big scientific meetings.
So it's kind of my joke. But it really is true that these are my opinions and not necessarily those of Young Survival Coalition
or the University of Illinois or any researcher that I may talk about, which I won't here.
But anyway, I'm going to skip over to my personal. This slide here is my biggest use for putting my horse on here.
I'm a horse person. And are there any other horse people? Just cancer people. Okay. I'll remember that.
This picture is special to me because it represents for me what is very personal,
a very personal relationship and connection that I have with my animal. It helped me heal through my cancer experience.
And so I wanted to start out by telling you that cancer becomes a very, it doesn't become,
it is a very personal experience for anyone who's affected by it.
And that is a huge motivation for me to be up here right now and to do the things that I've done,
to work with the people that I'm working with, to make a difference in our community,
and hopefully for young women all over the world.
My personal history, my personal cancer history, has actually become a code for my identity,
for how I fit into this complex ecosystem of cancer.
And I was talking, I kind of joke, we joke with each other, when you meet another cancer survivor,
you want to know all the details. So my details, my deets, I'm BRCA positive,
I was diagnosed with triple negative breast cancer at the age of 36.
I had bilateral mastectomy with no reconstruction.
And just by saying those words, not only my friends who have gone through this experience,
but my medical team, all of these implications about me and my future become a little bit clearer.
Not as clear as I'd like them to be, because I want to know exactly what are we targeting,
and how is that going to affect me, how is that going to affect the next person.
But it's this code that we speak once we're through diagnosis becomes our identity.
And that is really significant. And I'll talk about that as we go on.
And my personal story, my personal story, because I think there's a difference between your personal cancer history
and your personal story with cancer.
And my personal story has brought me to, again, this stage.
It's filled with all of these people.
And, you know, I feel like I'm going to cry now, because these people mean so much to me.
These are young survival survivors in Champaign-Urbana,
and their families, and their friends, and their caregivers.
Every single person in this picture is affected by breast cancer.
For a woman who was diagnosed under the age of 45, some of them in their 20s,
many of them in their 30s, some when they were pregnant with their children,
some of them, obviously you see they're young, and they're vibrant, and they're growing, and they have families.
And so that gives my story meaning.
By adding my story to their stories, we together can make a difference
in what is happening, hopefully, all the way to the bench,
all the way to what you're looking at. Those molecules under the microscope have a face.
The things that you're doing, those nanotechnologies,
that is exciting to me. I want to know, when is that coming, and how is that going to affect,
how is that going to help the person who's sitting next to me, who does have bone meds,
that I would love to get in there with my own hands and just take it out.
Give me those nanoparticles so that we can put it there and save her life.
And that's the face.
Young Survival Coalition is a national organization.
It was kind of a seed for bringing together all of these faces
and creating this circle of support and bringing women and men and families together.
It was also a vehicle for us to develop our voices
so that we could go to our oncologists
and researchers and let them know
what are those issues that are unique to us.
And when we're going through our treatment,
this is true for many of us, not just me,
but when we're going through our treatment, it feels like
that our issues aren't really being met.
Cancer, there's only like 10,000 cases of breast cancer
diagnosed in women 40 and under a year. That's really small
when you look at the numbers of cancer diagnoses.
But we do have our particular issues.
And so we have a vehicle for starting to make those connections between survivors
with our oncologists and with hopefully legislators
and changing the law and this discussion we had earlier about healthcare
and our system and these atrocities that happen when people are sort of skipped over
for reasons that shouldn't be there. This is where our voice starts.
And this page here, this is our Facebook page.
This is probably one of the most active pieces of our communication that we have right now.
And I want to focus a little bit now
on communication. You know, my background is in
linguistics and in teaching English as a second language. It has nothing to do with science.
Although when I was in seventh grade, they asked you, what do you want to do
when you grow up? And I said I wanted to be a biologist. So somewhere inside me there might be
a little scientist that wishes they could be in the lab. And at AACR, I went
there last year and I kind of really dug all that equipment that was in the exhibit hall.
So there's a little bit of biology geek in me, I think.
But really language is important for me.
And communicating. And how are we communicating to each other?
Because it's important for us to be able to
talk to our doctors so that when we go into their office
they are looking at us as an individual, as a person.
And not so much as that statistic on the wall or that case
study where the patient presents with such and such a disease and here are the steps that you
go through. It's like we want to be seen as the person that we are.
We want to be seen as that multi-dimensional being that's coming in your office
that not only has a physical tumor or some other
thing wrong with us, but we have psychosocial issues and we have
financial issues. And well, the oncologist, it's not your job
to really worry about our financial situations.
Our whole medical society, our whole
healthcare system needs to recognize all aspects of that. And when a patient
walks through the door, have something ready for them.
And I think we're getting closer and closer. And in our community, even,
I noticed a difference with Mills Breast Cancer Institute and they've changed.
And I'm not saying this is from me or from YSC or the women who are in this picture.
But our voices were heard and
every time I go into their office, there's something little new that happens that
I'm like, wow, I was complaining about this four years ago and now they're actually doing something about it.
It takes time everywhere, right?
When we go in and get our, what do they call it, the stats done
when you have your blood pressure taken and your temperature and the oxygenation in your blood
and whatever, now they measure our arm that was affected by
lymph node dissection. That just became part of
the process for checking a patient in. And it's too late for me
because I have lymphedema and they didn't catch it very early and I went through months
and months of treatment and it's a huge pain.
But I told them, I'm like, look, you might be helping the next woman
avoid some of the issues that I had to go through. And that's where our voices become
really powerful in this. I mentioned AACR
so I just wanted to put, so this was like a little business card.
I was part of the Scientist Survivor Program. This was part of my effort.
I think it's really important to be as educated as you possibly can.
If you want to be able to speak up. It's hard to sit here and ask a question
in a meeting when you really do only understand 65% or
lower of the presentation that's going on but you're trying really hard
and your brain is scrunching and you're trying to make that connection with, well,
this research is going to, if it goes in the way that
could happen, this is what it would look like once it's in the clinic.
And that is really exciting. But it takes a lot of work on the patient
side to be able to get to that point where these things start making sense.
And I kind of view a patient advocate in my role
as being a translator. And to translate
because language has a lot to do with it. But translator,
and I joked last night at dinner, I'm like, sometimes we need to have a translator come with
us into our oncologist's office to tell us what they're saying
to us. Not only do we not hear them because we're in total shock half the time, but just
so that we can start applying what they're saying to us in
real terms. And I said it jokingly, but as I listen to
presentations, I keep thinking that. We need to have, I know what you're saying.
I know what you're saying, but I really wish that it could be translated into
more common language.
And so that's kind of the role that I see my education
going so that I have a better understanding in real scientific, authentic situations
where I'm being paired with scientific mentors
and understanding the biology and the basic science
and the developments and what that meaning has so that when I come back
to my community, I can help be that translator person. I don't have to
push everybody into, hey, guess what you have to do? You have to go and start reading
cancer research and clinical trials and all these kinds of things, but
to help them understand how it applies to them. And I think that is really
key. Like I said, it takes a lot of time. And I'm going to share
with you a couple of things that were my big motivation for
putting a lot of energy into doing that particular piece of it. And these
are important because they scare the crap out of me. And I'm going to
add another one because Dan Heller's presentation, he
had another scary thing for me to add. So I'll be adding that. But one
of them is this I found. The leading cause of
cancer death in women ages 15 to 54 is a breast cancer of all the
cancers. The leading cause of cancer death. And I was diagnosed when
I was 35, 36. And the first time I saw that, I'm like,
holy crap. What does this mean? It means I'm going to
die. So you see these things and you're like, oh, my God. I have to do
something about this. What do I do other than get my treatment?
The second thing I saw, and this is from SEER data,
that there's cancer survival rates, and we hear this over and over again, and it's a great
media love to say this, that the survival rates
have increased dramatically over the past 20 years. Oh, yeah, sure.
It has. Except for, you know, 30 to 34,
35 to 39. Why is there a dip?
So that's changed a little bit now. But when I saw this and I was going through my treatment,
it scared the crap out of me. I'm like, what is going on?
How is this even possible that we're, that whole
demographic is being ignored? And is it being ignored in the research?
It just raised a lot of questions. And ultimately
I looked at this and I looked at the knowledge around me and I
looked at what I could glean from my doctors and my medical teams
and I just felt like there was a huge gap in what they could tell me.
And so I just decided that what we're doing now is not working.
It's not working if we're seeing huge
gaps in our survival rates of invasive cancers
over 20 years in one population segment.
It's not working if we're waiting for lifetimes to have
these breakthroughs happen. It's not working.
And so what can we as patients do
to push these agendas forward to
accelerate this progress? And there's a lot of things that we can do
and I just chose one thing to talk about today
because it's mostly connected with more of my linguistics and language background and communicating.
And that is finding a way so that we're connecting the science
to the patient and the patient to the science
or the scientist. And to do this better
so that we understand why those gaps are and so that we
can help communicate that these gaps and
these scary things are really urgent matters for us.
We need to get that point across. So
I'm looking at how do we do that? How do we start making it
easier for our researchers to talk
with the patient advocates? Because I hear a lot of people saying, oh yeah, we want
to talk with the patient advocate. We want to do this. And it doesn't happen so
easily. It's not natural. It's hard. It's hard. It's hard to cross over. It's hard
to be here, like I said, and to feel like you're an equal
part when you're only understanding half of what you're looking at. But
there are ways. And here's what I think. I think that if we
look at some of these statistics from Q Internet American Life Project, going
to just how Americans in general
are starting to use technology to share information.
Where are we getting our information? How are we using this technology
in our hands? And how can we leverage these
changes in our behavior and our expectations to
increase their communication, the connection, and the
understanding between the researchers, the
oncologists, and the patients? So 83%
of adults age 33 and younger use social networks. Okay, we all
figured that, right? But if you look at the
little thing in my pocket, if you look at the little chart, which I know
is really hard to see, there's a huge increase in
older generations, the silent generation, age 65 to 73,
huge increases are taking place. This is data from 2010
and it's huge.
Huge changes. So our behaviors are changing
for how we're doing these things. Every generation
is increasingly getting news online. So not just our paper
newspapers, but all
of our generations, every generation has an increase in getting
news online. This is any person who actually
accesses the internet. Because we know that there are also people who
not only are not getting medical care, but they also don't have access to
the internet and computers and cell phones and that type of thing. But this is
really significant when you start thinking about your own behaviors.
Of the internet users, 8 in 10
are looking for health information online.
That's a lot of people. It's the third most popular pursuit.
Just look at that. Your email and going to a search engine are the top two and then what's the
next thing people are doing once they hop online? They're looking for health
information. And that could be any kind of health information. That could be going to
WebMD to see why your pancreas is killing you. I don't know why they're
getting the hypochondriac person on there. But any kind of medical
pursuit. And the devices that they're using are
changing too. This is brand new data that just came out
from...this is showing an increase from May 2011 to February
2012. So less than one year.
And look at the percentage of owners of smart phones.
11% increase for smart phone owners. A decrease
in regular cell phone owners and a slight decrease in
no cell phone. So you see where the trends are going in one year. And if you
remember, let's see what is the...there's a great statistic. It took
nine years for a million users to get on AOL.
It took nine months for a million users to join Facebook.
And it took nine days for a million users to download, draw
something on your cell phone. I mean when you're looking
at this change in behavior and devices
and access, we have to start thinking about how
information is being consumed and shared
and interpreted by the individuals.
So 17%...and actually this data is 2011 data, not the
2012 that we just saw. So this is probably increased even more.
17% of cell owners have used their phone to
look up health or medical information. So not just going to the library
computer or their home computer, but using their cell phone. And that's
much greater for 18-29 year olds. So as
patients age, look at the behaviors that are following them and coming closer.
9% of these cell phone owners
have apps on their phones that help them track or manage their health.
I have like four of them because I tried them.
But look how many at 18-29 year olds.
59% of Gen Yers, people born
1965-1983, would switch doctors for one with better
online access. They just wouldn't go there anymore. If you can't give me
records online so that I can make appointments even or look at my
results or share that information with the people
that I want to share it with, I'm not even going to bother going to your office.
That's major too. It's a major change.
Does anybody have any questions on this before I go on?
This is all of the data
that I have. Just our own behaviors and what we
expect from our devices and where we're getting information.
And just thinking of my own experience, how do I
become an educated patient and a patient advocate?
The research that I find online is really important.
And not just the research that I'm finding online, but the communities that I can become a part of
and be an equal member of that are helping
me to stay current. So for example, using Twitter.
I didn't include the Twitter statistics. Twitter is like only 8%
of internet users are actually using Twitter. It's a pretty small percentage.
But almost twice that. I think it's like
27% of Latino and African-American
Americans are using Twitter.
So there's some different demographics if you break down even
what technologies people are using and why they're using them. But Twitter is a
back channel at a conference, say at AACR or ASCO or something like that.
It's a place where a patient advocate can actually have a voice.
Ask questions. Be in a session. Maybe
give a slightly different perspective. Here's what I'm thinking. It's a good
way to have that connection with a patient advocate without
causing everybody to come travel to a certain city.
They don't even have to be there. They don't even have to be at the conference to give that information.
But I found that the Twitter back channels have helped me to create my
network within a scientific community. They have
tweet ups. Are there any tweeters here? Anybody who's
using it professionally for your research
and your practice? So no 8%ers.
I'm surprised there's not at least one person
here who's used this before even at a conference or even followed
the Twitter feed of a conference.
Even beyond the conference, I have
those people I stay in their community and they
when a new study comes out or a new media item comes out, they
help me give perspective on whether that is something that is
fufu or if that's something that's serious. I have my professional
network right there. So that is really important. That is really key.
I would encourage you guys, especially the young folks, the young
researchers, to start getting connected in those ways.
Not just with patient advocates but with each other. There are a lot of resources
out there for that. So we've got about
20 minutes here and I do want to leave some time to ask questions.
I wanted to share a couple of things. This is from...these are actual quotes
that happen when the Young Survival Coalition comes together.
We meet every month and it's very casual. You all are
invited, if you're in town, to go to Jupiter's at the Crossing on the last Tuesday
of the month and meet us and have pizza and beer. You can hear real
raw stories. Sarah and Jay and Eric have all been there
and they've heard the raw stories. Maybe we can hear some of those stories
on the panel, I'm hoping. I just thought I would give you a sneak of what
I've heard people say at these meetings that
some of them scared me. I wouldn't do a clinical trial because I want
to guarantee that the treatment they give me will do something. Talk about
misconception about what a clinical trial is and does.
When that came up, there are several of us that have gone through clinical trials
have benefited greatly from being a part of a clinical trial.
We had the opportunity to talk with that person and tell them
the real experience of what a clinical trial does. They're not going to
give you a placebo and let you continue on.
It's real educational opportunities.
This is very common. I never saw anyone my age during treatment.
I think that's the whole reason Young Survival Coalition was established to begin with.
This one I wanted to punch this surgeon in the gut when I heard somebody say that.
My surgeon said lymphedema is just an annoyance.
As a lymphedema sufferer, it's more than an annoyance.
Especially when you're 36 years old and you expect to live another 50 years with this.
I had to insist that they do more tests on my lump
because they didn't believe that it would be breast cancer. They weren't giving me
the answers that I thought I needed to have.
When they did more tests, lo and behold, it wasn't just a lump.
It was actually a tumor that needed serious follow-up.
That's scary that that happens. These are not old quotes. We've been around since 2009.
These were collected in 2009. I don't know what my options
are after a mastectomy. That's another issue.
We happen to be in Champaign-Urbana, which is a really wonderful city.
We're really blessed to have the University of Illinois and such great
medical options, but we don't have every single
specialist that exists living and working in the Champaign-Urbana area.
Sometimes when you go and have a consult, you're only being
consulted about the things that are offered in that particular office.
Half of us don't even know that there are other options for certain
types of reconstruction or even other kinds
of treatments. That is a really serious issue. Part of what we do is
make sure that we are sharing options and bringing education
to this area. My husband doesn't know who to talk to.
That happens a lot, too. Or they need to talk, and yeah, there really
is not a comfortable place for them to go.
Those are just some snippets of what we have heard
in our meetings from the patient. In response to this, too,
the Young Survival Coalition, this will be our second
year doing this. On November
3rd, 2012, we're putting together a symposium.
It's for cancer patients
and thrivers, medical professionals.
We have oncologists there.
We want to have the whole strata of people who are involved with
cancer and cancer treatment diagnosis to
be here. We invite all of you to come. It's $10. It includes lunch.
We have speakers from all over the place coming.
If you're interested in being a speaker, let us know, too. We would love that.
That's all that I have prepared as sort of a background
from a patient perspective. The impetus for
taking your personal cancer history and your personal
story and making it into something bigger than just yourself.
Then reflecting on what it's like to be that patient who
has a foot in the scientific area who really wants
to see change and wants to support the research that's going out there
and seeing these huge communication challenges.
I hope that it's given you something to think about as you go home and phone
your significant others or text them or look at
Wikipedia to find out what the heck the next speaker's talking about.
These have serious impacts on all parts of our lives
and not just in cancer. That's something that we can all manage.
We can all look at how we're using these devices, how we're communicating with each other
and make an effort to connect in ways that are accessible
to all of us. Any questions?
Are there any questions?
We actually have a question.
We had discussions on the
lack of participation in breast cancer clinical trials.
It's fueled mostly by misconceptions such as if you're
not getting the therapeutic question
you're getting a sugar pill, which is not true for the standard of care for
what's being tested across the standard of care.
Do you know if there's a lot of positive enforcement in
the clinics in your coalition to participate?
Do you encourage participating in these trials?
Our nanogels have never become therapeutic.
I think clinical trials are incredibly important.
I was a beneficiary of a clinical trial that I am so glad
that I was part of.
When we get a new person come in and they start talking about their treatment
there are several of us who ask, did they talk to you about this?
If they're being treated at certain hospitals in the area
especially, we know that they probably haven't been talked to. They don't bring it up
because all they offer is a standard of care.
I know Jen wants to say something. She'll answer.
She's a good nurse.
I'm Jen Smith and I'm very excited to be on the panel and we'll share
a little bit more about my story. Clinical trials, I am stage four.
I would love to be in a clinical trial. I spend my days
making phone calls, doing research online, looking up possible
clinical trials and I'm turned down for a lot of them because either I'm too heavily
pretreated, I'm on my 16th treatment
or I didn't have enough time between
the original chemotherapy and the recurrence chemotherapy.
I had 364 days and I had to be one year out so I've been
turned down because of that. I've been turned down because although I have
exceptional insurance, they won't pay for standard of care costs even if
the drugs are provided free. So there are issues
that go beyond just wanting to do the clinical trial. There are so
many people that I know that would love to have that option
but can't afford standard of care costs or
risking losing insurance because you're trying to do a clinical trial.
So I would hope that in the future researchers are able
to do clinical trials and offer complete coverage for
participants in those trials.
I have a comment about that. We deal with this, at our
cancer center we probably have about 100 or 120 clinical trials
open at a given time and the ways of doing this are coming online and offline.
We try to have a broad portfolio available for
patients at every stage of disease and the thing that
we have to turn the public and the insurance
companies head around to is to think about in many cases
it would be after a certain treatment that you've been
through, you've been through the standard of care. Now the standard for you would be
investigational therapy. What I would say, not experimental,
investigational. This is not, we're trying to find
out if the drugs will work for you, they will work for
others, but it is an expensive procedure.
Medicare is actually, interestingly is
obliged to pay for the standard of care for clinical trials but
commercial insurance is not. Perhaps in Massachusetts there
we don't know the answer to that. I will say that
we try to augment, we often have a study that's a drug company
sponsored study. It's kind of interesting that our friends at pharmaceutical companies
really we take a look at what it costs us to mount these
trials, our regulatory fees which are always going up.
The extra time that the physicians and staff have
to spend, have to and need to spend with you to explain the trials
costs money. What we end up doing a good deal of
time is we end up putting hundreds and hundreds of thousands of dollars
of philanthropic money into our clinical trials enterprise
just to be able to get these trials out to you. We have to make choices
we can't do it all the time. But again, many cancer centers
they have NCI Cancer Center grant that pays part of the
clinical trials office but that's only maybe a third of the cost. We're putting
a lot of money into the enterprise. Criteria though
are often stretched because part of it is the idea
of doing no harm. Part of it is due to
sometimes trying to commercial concerns in companies.
They want to make sure that their drug is fairly tested and
if some adverse event occurs, it's
really not due to someone else's drug that was in their system or something like that.
But those are reasonable concerns because at the end of the day
their interest in yours coincide
because they would like to bring a new drug to treat what you have.
They want to be sure
nothing else gets in the way. I hear what you're saying and I want to assure you that
many of us in the basic and clinical research communities in cancer
are doing the best we can. With some
diminishing resources, I would say we have nationally funded
NCI funded clinical trials groups that they're encouraging
us to offer to bring more patients into trials, but
they're cutting our per patient fees such that
the federal government is giving us one third of the cost.
What can you do? I suggest that you
advocate for a health care system that you feel is the
right one. I can't tell you what that is.
And I suggest that you advocate for an increased
federal funding of research of every type in cancer
as an investment in our national security, investment of
our future, which I see here with all the trainees here, and
investment in our economic growth. So in every which way,
the NIH budget, the National Science Foundation budget,
the Department of Energy budget, these are the edges of growth of our country
and this is where we should be spending money to help us out of this terrible
recession in the past several years and to offer some new hope for people like yourself.
I agree. And I just saw this week
a breakdown of the U.S. budget and only 2% of the
entire U.S. budget is going to cancer research, to all cancer research.
2% goes to education as well. 20% is going to defense.
20% to Social Security and those projects. So when
you look at those programs and the amount of money that's actually going
into that, it was exactly, we need to be putting our voices
out there to get that funding. I think
just one comment on the patient recruitment issue,
it's kind of related in a way to this very graphic presentation we had right before
that got my goat, but patients just don't
understand what it means, not necessarily
that there's placebos involved or what have you, but
they don't understand the science, they don't understand that it's important
and most of the time they want to just be reassured that
they're getting the treatment, they trust their doctors. Many patients
don't even question the treatment that the doctors are recommending.
This is relative, if you talk to oncologists right now, the ones that I've
talked to, it's more becoming, it's generational, this questioning back.
And I think that goes back to a little bit of what I was talking about with the access
to this information too and that we're able to do our own research, maybe not understand it all
but we're able to get online. There are sites out there like breastcancertrials.org
where they do a really great job of breaking that
clinical trial protocol down into real language and say this is what's happening
and this is what you need to do to qualify for this. So having those kinds of resources.
But most people don't even know that those things exist. So there's
communication gaps all around and it's very expensive as was brought up
to take a patient through that process.
I have a question. Have you seen, which is YSCD's
survival coalition and other organizations
like YSCD, have you seen cases
where they work closely with politicians to restructure the healthcare system
or have advocates in Congress
to change the NSF budget and everything and also
allocate where the federal funds go
to research? There are a ton of
places for that. As you know, being a very active person, no not you
who I was talking to, Freddie, that's who I was sitting next to, he is very active
and we had a long discussion about One Voice Against Cancer as a group
that takes multiple charity, non-profit organizations
and they go to Washington and they have lobby days.
The National Breast Cancer Coalition also has lobby days where they train breast cancer
patient advocates and research advocates and then do lobby days
in Washington. Are they pretty effective?
Change takes a lot of time. I asked Freddie this last night too. I'm like, well have you seen any changes?
He's done this a couple of years now. He's like, well it takes a long time.
But knowing that if you're not in that office with that
congressman telling them what's important, then somebody else is going to be
sitting there and who knows what they're telling them is important.
That's one place for our voice. The more that you go to Washington, the more
you're talking to your legislators, your congressmen, and developing that
relationship so that they trust what you're saying, they trust your
organization, they trust you as an individual, you're going to start seeing that. It takes
lots of voices to make that happen.
What is the lack of change or the
reason change?
We should do a whole panel just on that because
we brought up several. Funding, if the government is not funding this, if the government
is constantly taking NCI funding away in a time when we
really need to be putting it into NCI,
we have a problem. But there are problems also in the reward system
for where research is taking place. What's being rewarded?
I probably shouldn't go into that here. I think that would be a good idea
for next year to have a panel kind of talking about that.
Thank you for a really great talk. I was curious,
I really appreciate what you're saying about patients needing
to get more informed using social media, getting that information.
Does that translate at all into patients not only
advocating for cancer research, but for advocating what type
of cancer research, what type of projects to put more money into
because the cancer research community is so huge.
Could that be another dimension to this movement?
Absolutely. I think that happens with, I hate to bring up the
devil right now, but the Susan G. Komen Foundation uses social media quite
a bit to contact their constituents and sign petitions
for certain directions in cancer research.
Social media is used as a way to show support. I think people
like this because there's minimal effort on their side to go and put their email
on a list. There are some downsides to
social media, I think, in terms of being real activist tools.
I think you can get
a great perspective. I might be stepping
out of my own experience realm a little bit, but just from using Twitter on my
own to understand what is going out there, what is important to
real people in the field, I get a better
understanding of the directions. They're opinions that I respect because I've grown
to know them and I know that they're respected in their own communities.
That helps me. I think I hinted to this before. There was a
media outlet. They take these
research discoveries that are so out
that I shouldn't even be making it to the paper. Suddenly it becomes this big hope
for everyone. I remember something about blueberries and mice.
It was a study with six mice.
The media had this, like, oh, look at this. If you have blueberry extract
it's going to prevent cancer, blah, blah, blah. I'm like, are you kidding me?
People on Facebook were passing this around. I'm like, wait a second. Read
what this really is. Go into the study and read what they're doing.
Six mice is a good indication that maybe that's something that
somebody would pick that up as further research. In terms of saying
that's going to do anything for a human being is a huge stretch. I think in a way
social media, but the media outlets have to be really
we need more responsibility from them too in how they're reporting this.
The scientific reporters.
We're going to transition into our panel discussion, so let's thank Leslie again for her time.
applause